Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …

Purpose This Phase 3, multicenter study (NCT03434041) was conducted in primarily
Chinese patients with treatment-resistant depression (TRD) to support the registration of …

Objective To evaluate the long-term safety and efficacy of intranasal esketamine in patients
with treatment-resistant depression from the Asian subgroup of the SUSTAIN-2 study …

Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …

Importance Approximately one-third of patients with major depressive disorder (MDD) do not
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …

Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

ABSTRACT Introduction: In March 2019, intranasal esketamine was approved by the Food
and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD) in …

Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-
resistant depression (TRD). Although existing studies have investigated the efficacy of ESK …

Aim: There is limited real-world evidence for patients with treatment-resistant depression
(TRD) receiving esketamine nasal spray. Methods: This retrospective cohort study used data …

Purpose To review the efficacy, safety, and place in therapy of intranasal esketamine, a
treatment modality for treatment-resistant depression. Summary An electronic literature …